Dysfunctional NO synthesis, as well as excessive ROS production, both linked to altered mechanosignaling (Figure 4), are consistently implicated in the pathophysiology of IHD and therefore, eNOS and NOX represent interesting therapeutic targets. The gene discussed is NOS3; the disease is myocardial ischemia.